Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caelyx + cisplatin + continuous infusion fluorouracil in locally advanced breast cancer
2006-004856-19Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- May 2007
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, cisplatin and fluorouracil in breast cancer, sponsored by European Institute of Oncology. Primary endpoints: objective response to treatment and pathological complete remission rate. Started May 2007; status: completed.
02
Drugs
pegylated liposomal doxorubicincisplatinfluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2006-004856-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004856-19.